Ziplex automated gene-expression system featured as platform of choice on Health Technology Exchange Web site - www.htx.ca
WELLESLEY, Mass., June 4 /PRNewswire/ -- Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced that it has met the goals of a $127,000 HTX/CIHR grant, reducing sample-preparation time from 2.5 days to less than eight hours. According to Xceed President and CEO, David Deems, the company continues its commitment to streamlining and speeding up sample preparation even further. Its ultimate goal is to enable researchers to turnaround results from sample preparation through gene-expression analysis in one eight-hour shift.
“The analysis time for gene-expression studies is substantially faster using the company’s Ziplex Automated Workstation than it is on other platforms -- three hours for Ziplex, compared to days for gene-chip systems,” said Mr. Deems. “But the pre-analysis time, regardless of the system, has been a limiting factor. Xceed partnered on the grant with University Health Network (the group of teaching hospitals associated with the University of Toronto) to achieve substantial time savings in sample preparation. HTX’s support has been critical to our success. And we were honored to have our Ziplex System recently featured as HTX’s spotlight technology on its Web site (www.htx.ca).”
The Ziplex System, which won an R&D 100 award from R&D Magazine in 2008, is rapidly becoming the platform-of-choice for leading institutions performing translational research. The system standardizes and streamlines gene-expression services, while saving valuable staff time and ensuring the most reliable results. Xceed designed the Ziplex System with turnkey functionality and significant advances in automation, array format, parallel sample processing, and analytics to minimize complexity, user interaction, and variability between users and sites.
About htx (www.htx.ca)
The Health Technology Exchange was incorporated in 2004 with one overarching goal - to accelerate the development of the Medical and Assistive Technologies (MAT) cluster in Ontario by helping Ontario-based companies develop and commercialize innovations. Its core programs and services include Research & Development and Commercialization & Market Development, which assists the MAT sector from product evaluation, company creation, and commercialization to international market readiness.
About Xceed Molecular (www.XceedMolecular.com)
Xceed’s vision is to advance molecular diagnostics by successfully translating novel multiplex tests into routine clinical practice and to create robust diagnostic solutions to improve disease outcomes. Our products comprise the award-winning Ziplex System for automated gene-expression analysis (available in the US and Canada for research use only), gene-expression services, and pre-configured arrays - Xpress Chips. Xceed is also developing multiplexed genomic tests for the Ziplex platform, both internally and with strategic partners. Xceed’s R&D and manufacturing are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts.
CONTACT: Media Contact: Caroline Grossman for Xceed Molecular,
+1-781-771-5579, caroline.grossman@gmail.com; Stephen Read of Xceed
Molecular, +1-508-242-5275, sread@xceedmolecular.com
Web site: http://www.xceedmolecular.com/
